Related Experiment Video
Updated: Jan 7, 2026

Author Spotlight: In Vivo Assessment of Thyroid Hormone Disruption Using the THAI Mouse Model
Published on: October 6, 2023
Assessment of Drug Induced Thyroid Dysfunction Risk Using the United States Food and Drug Administration Adverse
Ruixue Li1, Tianqi Liu2, Ting Li3
1Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing, PR China; Department of Pharmacy, Xizang Autonomous Region People's Hospital, Xizang, PR China; Department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical Sciences, Peking University, Beijing, PR China.
Objective:
To quantify drug-specific associations with thyroid dysfunction (TD) using data from FDA Adverse Event Reporting System and to identify agents with significant disproportionality signals.
Methods:
Using data from FDA Adverse Event Reporting System (Q1 2004 to Q1 2025), disproportionality analysis (reporting odds ratio; Bayesian confidence propagation neural network) was employed to assess signals of drug-induced TD. Univariate analysis, least absolute shrinkage and selection operator (LASSO) regression, and multivariate logistic regression were applied to identify independent risk factors. Time-to-onset analysis was used to evaluate the timing of TD following drug initiation.
Results:
A total of 44 317 reports associated with TD were identified, with a higher proportion involving female patients (60.3%). The median patient age was 59 years (interquartile range [IQR]: 45-69 years). Signal detection identified 172 suspect drugs significantly associated with TD. Following disproportionality screening, drug candidates with a reporting odds ratio whose 95% confidence interval lower bound exceeded 1, cell count a > 100, and P-adjust < 0.01 were advanced to LASSO regression. LASSO identified 43 drugs associated with TD. In the multivariable logistic regression model, female sex, the 45-59-year age group, and the 43 drugs were independent risk factors for drug-associated TD. Furthermore, the median time-to-onset for drug-induced TD was 34 days (IQR: 7-105 days), with approximately 75% of cases occurring within the first 100 days of drug initiation.
Conclusion:
This study identified multiple drugs significantly associated with TD and highlighted sex, age, and specific medications as independent risk factors. These findings support improved pharmacovigilance and clinical awareness of drug-induced TD.
More Related Videos
16:02Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
Published on: February 10, 2023
05:41Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis
Published on: February 9, 2024
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation
FDA Approved Drugs: Changes to Approved Drugs
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Therapeutic Drug Monitoring: Affecting Factors